Recombinant human Neprilysin /CD10 Protein, Tag free, 50µg

Background
Cluster of differentiation 10 (CD10), membrane metallo-endopeptidase, neutral endopeptidase (NEP), Neprilysin, and common acute lymphoblastic leukemia antigen (CALLA), is a 90-110-kDa type II transmembrane glycoprotein normally expressed by a variety of tissues, including epithelial cells of the prostate, kidney, intestine, endometrium, adrenal glands, and lung. This zinc-dependent metalloprotease enzyme cleaves peptide bonds on the amino side of hydrophobic residues and inactivates a variety of physiologically active secreted peptides. CD20 is thought to be the rate-limiting degrading enzyme of amyloid β peptide (Aβ) whose abnormal misfolding and aggregation in neural tissue has been implicated in the development of Alzheimer\'s disease (AD). CD10 is also identified as the common acute lymphoblastic leukemia antigen (CALLA) present on leukemic cells of pre-B phenotype, and thus serves as the most important biomarker in the diagnosis of human acute lymphocytic leukemia (ALL).

Source
Recombinant Human Neprilysin, Tag Free (MME-H521b) is expressed from human 293 cells (HEK293). It contains AA Tyr 52 - Trp 750 (Accession # NP_000893.2).

Molecular Characterization
This protein carries no "tag".
The protein has a calculated MW of 80.0 kDa. The protein migrates as 80-100 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Endotoxin
Less than 1.0 EU per μg by the LAL method.

Purity
>95% as determined by SDS-PAGE.

Formulation
Lyophilized from 0.22 μm filtered solution in 20 mM Tris, 100 mM NaCl, pH8.0 with trehalose as protectant.

Reconstitution
See Certificate of Analysis for details of reconstitution instruction and specific concentration.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70^°C for 3 months under sterile conditions after reconstitution.

Clinical and Translational Updates

(1) "Impact of Insurance Status and Region on Angiotensin Receptor-Neprilysin Inhibitor Prescription During Heart Failure Hospitalizations"
Davogustto, Wells, Harrell et al
JACC Heart Fail (2024)
(2) "Efficacy of early administration of sacubitril/valsartan after coronary artery revascularization in patients with acute myocardial infarction complicated by moderate-to-severe mitral regurgitation: a randomized controlled trial"
Yin, Ma, Zhou et al
Heart Vessels (2024)
(3) "Association between Visit Frequency, Continuity of Care, and Pharmacy Fill Adherence in Heart Failure Patients"
Hamo, Mukhopadhyay, Li et al
Am Heart J (2024)
Showing 1-3 of 7031 papers.